Roche announced Monday that Bill Anderson, CEO of its pharmaceuticals division, will step down after nearly four years at the helm.
His last day will be Dec. 31, Roche said, as Anderson leaves to “pursue opportunities outside of Roche.” A successor will be appointed by March, the company added.
Anderson’s departure comes at the end of a rocky year for the Swiss drugmaker. The company watched two of its most closely watched candidates fail to yield results in late-stage trials: An experimental amyloid-clearing antibody failed to slow Alzheimer’s patients’ cognitive decline, and an experimental antibody for a new, highly anticipated, immuno-oncology target called TIGIT failed to slow tumor growth in two different cancers.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.